Blog

10 Sep

Sorrento Therapeutics, Inc. Receives Court Approval for “First Day” Employee Wages and Cash Management Motions

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

News

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

News

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...

10 Sep

News

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

September 10, 2024
Posted by oqorypharma
Leave a comment

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic...